Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Angiotensin Ii. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.69 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.69 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.60 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 4/20 | 0.56 |
| ▸ | APLNR | P35414 | 1/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL22125774 | 1.00 | AGTR2 (0.69) | AGTR2AGTR1C5AR1EPHA2F2 | |
| Angiotensin Ii SCHEMBL9013950 | 1.00 | AGTR2 (0.69) | AGTR2AGTR1C5AR1EPHA2F2 | |
| Angiotensin Ii SCHEMBL29757879 | 1.00 | AGTR2 (0.69) | AGTR2AGTR1C5AR1EPHA2F2 | |
| SCHEMBL30445863 | 1.00 | AGTR2 (0.69) | AGTR2AGTR1C5AR1EPHA2F2 | |
| Angiotensin Ii SCHEMBL28966994 | 0.99 | AGTR2 (0.68) | AGTR2AGTR1C5AR1EPHA2F2 | |
| Angiotensin Ii SCHEMBL30960106 | 0.99 | AGTR2 (0.68) | AGTR2AGTR1C5AR1EPHA2F2 | |
| SCHEMBL24454648 | 0.98 | AGTR2 (0.69) | AGTR2AGTR1C5AR1EPHA2F2 | |
| SCHEMBL29701256 | 0.97 | AGTR2 (0.65) | AGTR2AGTR1C5AR1EPHA2F2 | |
| SCHEMBL29359023 | 0.97 | AGTR2 (0.66) | AGTR2AGTR1C5AR1EPHA2F2 | |
| SCHEMBL29976758 | 0.97 | AGTR2 (0.65) | AGTR2AGTR1C5AR1EPHA2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| CN-118005714-A | Soybean peptide with low bitter taste and high ACE (angiotensin converting enzyme) inhibitory activity as well as preparation method and application thereof | 华南理工大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-116375790-B | Microfluidic chip solid-phase peptide synthesis method and device | 厦门胜泽泰医药科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116375790-A | Microfluidic chip solid-phase peptide synthesis method and device | 厦门胜泽泰医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11453869-B2 | Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses | AVIRMAX, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220160816-A1 | ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO | LA JOLLA PHARMA, LLC | 2022-05-26 | — | — | US | disclosed |
| US-20220064618-A1 | Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses | AVIRMAX, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20190183962-A1 | ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO | LA JOLLA PHARMA, LLC | 2019-06-20 | — | — | US | disclosed |
| US-5571680-A | FLUORESCENCE, ENZYMES, PROTEINS, DIGOXIGENIN, QUANTITATIVE ANALYSIS | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183962-A1 | ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO | ACE, AGT, AGTR2 | AGTR1 4/4885AGTR2 3/4885C5AR1 556/4885 |
| US-20220160816-A1 | ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO | ACE, AGT, AGTR2 | AGTR1 4/4885AGTR2 3/4885C5AR1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.